Home › Funds › Casdin Capital › BEAM

Casdin Capital position in BEAM

BEAM THERAPEUTICS INC · Health Care

Casdin Capital reported holding 1,500,000 shares of BEAM (BEAM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$36.7M, representing 1.60% of its reported portfolio and ranking #12 among its reported holdings. Casdin Capital has disclosed BEAM holdings in 24 of the last 24 reported quarters, going back to Q4 2020.

Latest position (Q3 2026)1.50M sh
Reported value held$36.67M
Portfolio Weight1.60%
First reportedQ4 2020
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Casdin Capital's BEAM position evolved

Casdin Capital first disclosed a stake in BEAM in Q4 2020 at 460,000 shares (US$37.6M). The position peaked in Q2 2021 at 818,820 shares, worth US$105.4M. Across 24 filings, Casdin Capital increased the stake 9 time(s), trimmed it 4 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 1,500,000 shares valued at US$36.7M — an increase of 150,000 shares quarter over quarter.. Notable position changes include a 78% increase in Q1 2021 (shares rose 61% over the following quarter), a 54% trim in Q2 2022 (shares rose 22% over the following quarter), a 61% increase in Q4 2024 (shares fell 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2020 460.00K $37.55M New
Q1 2021 818.82K $65.54M Add
Q2 2021 818.82K $105.39M Hold
Q3 2021 818.82K $71.25M Hold
Q4 2021 818.82K $65.25M Hold
Q1 2022 818.82K $46.92M Hold
Q2 2022 375.00K $14.52M Reduce
Q3 2022 370.00K $17.63M Reduce
Q4 2022 370.00K $14.47M Hold
Q1 2023 570.00K $17.45M Add
Q2 2023 570.00K $18.20M Hold
Q3 2023 570.00K $13.71M Hold
Q4 2023 528.00K $14.37M Reduce
Q1 2024 675.00K $22.30M Add
Q2 2024 675.00K $15.82M Hold
Q3 2024 775.00K $18.99M Add
Q4 2024 1.25M $31.00M Add
Q1 2025 1.43M $27.84M Add
Q2 2025 1.45M $24.66M Add
Q3 2025 1.60M $38.83M Add
Q4 2025 1.60M $44.35M Hold
Q1 2026 1.35M $32.17M Reduce
Q2 2026 1.35M $46.33M Hold
Q3 2026 1.50M $36.67M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BEAM and 13F data

BEAM (BEAM THERAPEUTICS INC) is a Health Care company. 27 other funds we track also report a position in BEAM — the largest reported positions include Farallon Capital Management (US$351.3M), ARK Invest (US$288.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$251.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BEAM

All BEAM fund holders →

FAQ

How long has Casdin Capital held BEAM?

Casdin Capital has disclosed BEAM holdings in 24 of the last 24 reported quarters, going back to Q4 2020.

What is Casdin Capital's current position in BEAM?

As of Q3 2026, Casdin Capital holds 1.50M shares of BEAM (BEAM THERAPEUTICS INC), valued at $36.67M, representing 1.60% of its reported portfolio and ranking #12.

Has Casdin Capital been buying or selling BEAM?

In the latest 13F filing (Q3 2026), Casdin Capital increased its position in BEAM. The position peaked in Q2 2021 at 818.82K shares.

Which other funds hold BEAM?

Other major institutional holders of BEAM include Farallon Capital Management, ARK Invest, FARALLON CAPITAL MANAGEMENT, L.L.C., among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.